TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group.

[1]  D. Lyon,et al.  Symptom clusters and quality of life in survivors of lung cancer. , 2006, Oncology nursing forum.

[2]  A James O'Malley,et al.  Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. , 2006, Journal of the National Cancer Institute.

[3]  R. Stock,et al.  Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. , 2006, International journal of radiation oncology, biology, physics.

[4]  J. Bourhis,et al.  Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Goodman,et al.  Adverse Events: The More You Search, the More You Find , 2006, Annals of Internal Medicine.

[6]  A. Avins,et al.  Brief Communication: Better Ways To Question Patients about Adverse Medical Events , 2006, Annals of Internal Medicine.

[7]  J. Buckner,et al.  Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Carles,et al.  Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Beam,et al.  Variations in Adverse Event Reporting in Phase III Head and Neck Trials (1990 to 2003): A Systematic Review , 2005 .

[10]  J. Baselga,et al.  Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Christopher U. Jones,et al.  Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Doroshow.  The role of the National Cancer Institute in drug development. , 2005, Clinical advances in hematology & oncology : H&O.

[13]  A. Garden,et al.  Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Jacobs,et al.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.

[15]  S. Bentzen,et al.  The need for adverse effects reporting standards in oncology clinical trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Weber,et al.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. , 2003, The New England journal of medicine.

[17]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[18]  J. Ensley,et al.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Sargent,et al.  Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Gwede,et al.  Assessment of toxicity in cooperative oncology clinical trials: the long and short of it. , 2002, The Journal of oncology management : the official journal of the American College of Oncology Administrators.

[21]  G. Di Lorenzo,et al.  Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Raisch,et al.  Variability in the assessment of adverse events in a multicenter clinical trial. , 2001, Clinical therapeutics.

[23]  J. Ioannidis,et al.  Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. , 2001, JAMA.

[24]  A Trotti,et al.  Toxicity in head and neck cancer: a review of trends and issues. , 2000, International journal of radiation oncology, biology, physics.

[25]  Jay S. Cooper,et al.  A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 , 1999 .

[26]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.